In: International Journal of Infectious Diseases, 2017, vol. 61, p. 1–2
|
In: BMC Infectious Diseases, 2015, vol. 15, p. 512
Extended-spectrum β-lactamases producing Escherichia coli (ESBL-E) are increasingly identified in health care facilities. As previously done for the control of methicillin-resistant Staphylococcus aureus, many hospitals have established screening strategies for early identification of patients being carriers of ESBL producers in general and ESBL-E in particular, and have implemented contact...
|
In: Enfermedades Infecciosas y Microbiología Clínica, 2014, vol. 32, no. 10, p. 623–624
|
In: Diagnostic Microbiology and Infectious Disease, 2015, p. -
The dissemination of carbapenemase-producing bacteria worldwide is an important source of concern because carbapenemase producers are multidrug resistant (Nordmann and Poirel, 2014). National guidelines increasingly recommend a systematic screening of at least carbapenemase-producing Enterobacteriaceae (CPE) and glycopeptide-resistant enterococci (GRE) in patients admitted to hospitals who have...
|
In: Antimicrobial Agents and Chemotherapy, 2015, p. AAC.04450–14
Resistance to ß-lactams is constantly increasing, due to the emergence of totally new enzymes, but also to the evolution of pre-existing ß-lactamases. GES-1 is a clinically-relevant extended-spectrum β-lactamase (ESBL) hydrolyzing penicillins and broad-spectrum cephalosporins, but sparing monobactams and carbapenems. However, several GES-1 variants (i.e. GES-2 and GES-5) previously identified...
|
In: Journal of Medical Microbiology, 2014, vol. 63, no. Pt_5, p. 772–776
|
In: Antimicrobial Agents and Chemotherapy, 2014, p. AAC.02695–14
The whole sequence of plasmid pENVA carrying the extended-spectrum ß-lactamase gene blaCTX-M-15 was determined. It has been identified from a series of clonally-related Klebsiella pneumoniae ST274 strains recovered from companion animals. This plasmid was 253,984-bp in-size and harbored, in addition to blaCTX-M-15, a large array of genes encoding...
|
In: BioMed Research International, 2014, vol. 2014, p. e249856
The emergence of one of the most recently described carbapenemases, namely, the New Delhi metallo-lactamase (NDM-1), constitutes a critical and growingly important medical issue. This resistance trait compromises the efficacy of almost all lactams (except aztreonam), including the last resort carbapenems. Therapeutical options may remain limited mostly to colistin, tigecycline, and fosfomycin....
|
In: Antimicrobial Agents and Chemotherapy, 2014, vol. 58, no. 5, p. 2929–2933
Twenty-two consecutive carbapenem-resistant enterobacterial isolates were recovered from patients hospitalized between January and April 2013 in different units at a university hospital in Istanbul, Turkey. These were Klebsiella pneumoniae isolates producing the carbapenemases OXA-48, NDM-1, and KPC-2, Enterobacter cloacae isolates producing NDM-1, and Escherichia coli isolates producing OXA-48....
|
In: Antimicrobial Agents and Chemotherapy, 2014, vol. 58, no. 5, p. 2976–2978
The carbapenem-hydrolyzing class D β-lactamase OXA-253 was identified in an Acinetobacter baumannii clinical isolate belonging to sequence type 113 (ST113) in Brazil. OXA-253 shares 93.8% amino acid identity with OXA-143. The blaOXA-253 gene is located on a ca. 20-kb plasmid. The genetic environment of the blaOXA-253 gene shares the highest identity with...
|